Eris Lifesciences soars 10% on JV with MJ Biopharm to enter insulin segment
The purpose of entering into the agreement is expansion of product portfolio to offer biotherapeutic options to the patients in cardio-metabolic segment, Eris said in statement
No comments:
Post a Comment